Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Theseus Pharmaceuticals, Inc. (THRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 SC 13G/A FMR LLC reports a 0% stake in THESEUS PHARMACEUTICALS INC
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023"
07/19/2023 4 GORDON CARL L (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Bought 328,482 shares @ $3.05, valued at $1M
Bought 151,450 shares @ $3.05, valued at $461.9k
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/19/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/19/2023 4 Foresite Capital Management V, LLC (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Bought 523,450 shares @ $2.97, valued at $1.6M
Bought 176,550 shares @ $2.97, valued at $524.4k
07/19/2023 SC 13D/A Foresite Capital Fund V, L.P. reports a 12.6% stake in Theseus Pharmaceuticals, Inc.
07/13/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/25/2023 8-K Investor presentation
Docs: "Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST",
"TARGET ALL KEY MUTATIONS SELECTIVITY AND LONG-TERM TOLERABILITY 3"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results"
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/14/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 39.6% stake in Theseus Pharmaceuticals, Inc.
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
03/02/2023 4 Rivera Victor (Chief Scientific Officer) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Granted 16,250 restricted stock units @ $0
03/02/2023 4 Shakespeare William (See Remarks) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Granted 21,250 restricted stock units @ $0
03/02/2023 4 Kerstein David (Chief Medical Officer) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Granted 17,500 restricted stock units @ $0
03/02/2023 4 Dahms Bradford D. (CFO) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Granted 17,500 restricted stock units @ $0
03/02/2023 4 CLACKSON TIMOTHY P (President and CEO) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Granted 45,625 restricted stock units @ $0
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/23/2023 SC 13G Frazier Life Sciences Public Fund, L.P. reports a 5.8% stake in Theseus Pharmaceuticals, Inc.
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Legal notice and forward - looking statements 2 ©2023 Theseus Pharmaceuticals. Certain statements included in this presentation are not historical facts but are forward - looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward - looking statements generally are accompanied by words such as "believe ," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," “on track,” "predict," "potential," "seem," "seek," "future," "o utl ook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a st atement is not forward - looking. The...",
"Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL"
01/03/2023 SC 13D/A Foresite Capital Fund V, L.P. reports a 12.4% stake in Theseus Pharmaceuticals, Inc.
01/03/2023 4 Foresite Capital Management V, LLC (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Bought 250,000 shares @ $5, valued at $1.3M
Bought 250,000 shares @ $5, valued at $1.3M
01/03/2023 4 HAYDEN DONALD J JR (Director) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Bought 100 shares @ $5, valued at $500
Bought 9,900 shares @ $4.9989, valued at $49.5k
12/01/2022 4 Dahms Bradford D. (CFO) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Bought 1,502 shares @ $6.657, valued at $10k
11/09/2022 4 GORDON CARL L (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.
Txns: Bought 192,000 shares @ $5.21, valued at $1M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy